Seattle Genetics (SGEN) Initiates ADCETRIS Phase II in New HL Patents Over 60

Seattle Genetics, Inc. (Nasdaq: SGEN) announced the initiation of a phase II clinical trial evaluating ADCETRIS (brentuximab vedotin) as a front-line therapy for patients age 60 or older with newly diagnosed Hodgkin lymphoma (HL). The trial is designed to assess the efficacy and tolerability of ADCETRIS as a monotherapy for older HL patients who have received no prior treatment. Seattle Genetics is the leader in the field of antibody-drug conjugates (ADCs) and ADCETRIS is an ADC directed to CD30 for relapsed HL and systemic anaplastic large cell lymphoma (sALCL).

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Getty Realty discloses separation terms for departing accounting officer
• Pyxis Oncology (PYXS) files for 39.2M share offering by selling stockholders
• Holcim to acquire Fermacell from James Hardie for EUR 840M